- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Presentation 7: Where Does HEOR Fit in the Oncology Model?
According to Dr Ramsey, both the Health Economics Outcomes Research (HEOR) model and the pharmaceuticals pricing model in the United States are broken. He says: Unless we, as a community, figure out a way to use health economics in our decision making, we are not going to stop this train of unsupportable price increases in pharma.
According to Dr Ramsey, both the Health Economics Outcomes Research (HEOR) model and the pharmaceuticals pricing model in the United States are broken. He says: “Unless we, as a community, figure out a way to use health economics in our decision making, we are not going to stop this train of unsupportable price increases in pharma.”
HEOR is defined as a multidisciplinary approach that is aimed at estimating value. This value usually includes costs and outcomes, as well as factors such as looking at the budget impact of new technologies, patient-reported outcomes, practice patterns, comparative effectiveness, and cost- effectiveness.
Dr Ramsey argues that unless we look at value and cost, the outcomes and research have little meaning. We cannot make good decisions and improve value for patients until cost and quality are taken into account.
“I think we need to put the H-E back into HEOR and figure out ways, as a community, for using that as a leverage point for breaking the current price trend in oncology,” he says.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Danziten for Chronic Myeloid Leukemia Without Mealtime Restrictions
November 14th 2024The FDA has granted approval to Azurity Pharmaceuticals' nilotinib tablets (Danziten), a novel version of the tyrosine kinase inhibitor for chronic myeloid leukemia that can be taken without mealtime restrictions.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
